Coral Gartner Australia

Professor Coral Gartner is the director of the National Health and Medical Research Council-funded Centre of Research Excellence on Achieving the Tobacco Endgame based at the University of Queensland. She is also an Australian Research Council Future Fellow, the Australian country lead for the ITC Project, lead researcher of the Interdisciplinary Tobacco Endgame Research Network funded by a National Health and Medical Research Council grant, and is the chair of the Editorial Advisory Board for Tobacco Control, the leading international journal in the tobacco control field. Professor Gartner has a disciplinary background in Environmental Health and Epidemiology. Since completing her PhD in 2006, her research has focussed on tobacco control policy.
Job Title
Director, Centre of Research Excellence on Achieving the Tobacco Endgame
Faculty / Department / Division
School of Public Health
Institution / Organisation
The University of Queensland

19 November 2026, Thursday

Time Session
08:30
13:20
Henry Marshall Chairperson Australia
Nurhayati Mohd Marzuki Chairperson Malaysia
  • Henry Marshall Speaker Australia
    Nurhayati Mohd Marzuki Speaker Malaysia
  • Siti Munira Yasin Speaker Malaysia
    The increasing use of electronic cigarettes and heated tobacco products has raised concerns about their potential health effects, particularly among younger populations. This presentation explores the evolution of nicotine delivery devices and how differences in device design, chemical composition and heating mechanisms influence toxicant exposure. Although electronic cigarettes and heated tobacco products may produce lower levels of certain harmful chemicals compared to conventional cigarettes, they still expose users to nicotine, reactive carbonyls, metals and other potentially harmful substances. The presentation discusses how these chemicals contribute to oxidative stress, inflammation, respiratory injury and cardiovascular effects. Emerging nicotine analogues and changing patterns of product use pose further challenges in understanding their long-term health consequences. Particular attention is given to the Malaysian context, including dual use, smoking cessation and regulatory challenges. Understanding these differences is essential for clinicians to communicate health risks effectively, support informed decision-making and promote evidence-based tobacco cessation strategies. Keywords: Electronic cigarettes, heated tobacco, toxicology, nicotine, respiratory health.
  • Amer Siddiq Amer Nordin Speaker Malaysia
    Smoking cessation is a key component of respiratory care, yet effective counselling must address differences in readiness to quit, personal beliefs and sociocultural context. This presentation examines practical behavioural interventions that pulmonologists can integrate into routine clinical encounters with culturally diverse Asia-Pacific populations. Using clinical scenarios, the session explores brief advice through the 5As and 5Rs, motivational interviewing using open-ended questions, affirmations, reflective listening and summarising, and cognitive behavioural strategies for managing cravings, challenging unhelpful beliefs and preventing relapse. The stages-of-change framework provides a practical approach to understanding readiness and tailoring conversations to patients’ needs. Cultural adaptation is considered through patients’ language preferences, health beliefs, family relationships and social norms surrounding tobacco use. Emphasis is placed on respectful, collaborative communication that elicits patients’ own reasons for quitting and supports achievable behavioural goals. Participants will gain practical approaches to initiating cessation conversations, addressing ambivalence and responding constructively to lapses. Integrating these approaches with appropriate pharmacotherapy and follow-up offers pulmonologists a comprehensive framework for supporting sustained smoking cessation across diverse clinical settings.
  • Suthat Rungruanghiranya Speaker Thailand
    "Tobacco dependence remains the leading single cause of preventable global morbidity and mortality, accounting for over 7 million deaths annually among 1.3 billion tobacco users worldwide. An acute global equity gap persists: 80% of all tobacco users reside in Low- and Middle-Income Countries (LMICs), yet population-level access to World Health Organization (WHO) best-practice cessation services stands at only 4% in low-income countries and 11% in middle-income countries, compared to 28% in high- income countries (HICs). While HIC treatment guidelines rely heavily on insurance-covered, high-cost first-line pharmacotherapies such as Varenicline ($400–$500 per course) and combination nicotine replacement therapy (NRT), LMIC populations face a severe economic hurdle where the out-of-pocket cost for a single month of NRT frequently exceeds the cost of continuing to smoke. This presentation evaluates strategies to bridge this global divide by analyzing the neurobiological imperatives of tobacco addiction, comparing clinical treatment guidelines, and introducing high-efficacy, low-cost pharmacotherapy combined with scalable community delivery models. Neurobiological evidence confirms that tobacco dependence is a physiological receptor-driven addiction requiring pharmacotherapy, which quintuples cessation success compared to unassisted quit attempts (~25% vs ~5%). Cytisine—a plant-based partial α4β2 nicotinic receptor agonist costing ~$20–$30 per treatment course—emerges as a transformative solution for LMICs. Clinical evidence from the randomized, double-blind Thai STEP trial (Respirology 2024; n=1,086) demonstrated that a 25-day course of locally manufactured Cytisine achieved non-inferior continuous abstinence rates compared to a 12-week course of Nortriptyline (10% at 12 months) with favorable tolerability. To operationalize these findings in resource-constrained health systems, a three-tiered LMIC master-algorithm is presented: task-shifting initial screening (Ask & Advise) to Community Health Workers, scaling automated mobile mCessation behavioral support, and providing generic Cytisine. Because global tobacco control 's primary challenge is structural rather than scientific, pairing affordable essential medicines with community-based participatory care offers a proven, equitable path toward reducing global tobacco mortality."
  • Coral Gartner Speaker Australia
    This workshop will discuss the harm minimisation framework of the three pillars of demand, supply and harm reduction as it applies to tobacco and nicotine products. The tobacco industry’s misuse of the ‘harm reduction’ concept and industry promotion of e-cigarettes and other non-therapeutic nicotine products will be explored. Participants will think through how the harm reduction concept of safer supply might be applied to tobacco and nicotine products. The Australian Pharmacy-only model for e-cigarette supply will be discussed as a real-world pragmatic example of a supply model that is consistent with a harm minimisation framework, in contrast with the industry’s preferred model of general retail supply via a ‘consumer product’ model.
  • Ser Hon Puah Speaker Singapore
  • Coral Gartner Speaker Australia
    Both health and non-health related workplaces and community settings can be engaged to deliver cost-effective smoking cessation interventions and to encourage adoption of smokefree workplaces and homes. The presentation will discuss the case study of the 10,000 Lives regional program that recruited champions from multiple organisations within the Central Queensland Hospital and Health Service Area. The initiative focused on increasing uptake of existing programs, including delivery of brief interventions, referral to the Quitline and promoting adherence to smokefree laws. Participants will be encouraged to consider a wide range of community and workplace partners who could be potential partners.
  • Suthat Rungruanghiranya Speaker Thailand
    Tobacco use remains the leading preventable cause of death across the Asia-Pacific region, yet this area also demonstrates that comprehensive, well-financed, and industry-insulated legislation can effectively reduce smoking prevalence. This summary explores the legislative and governance frameworks essential for robust tobacco control, primarily focusing on the WHO Framework Convention on Tobacco Control (FCTC) and the MPOWER technical package. Effective governmental strategies require simultaneous implementation of multiple measures, including progressive excise taxation, comprehensive smoke-free laws, and standardized packaging with pictorial health warnings. Furthermore, securing earmarked and transparent financing, as exemplified by Thailand's Health Promotion Foundation (ThaiHealth), provides the operational continuity necessary to sustain long-term public health campaigns. A persistent challenge in the region is tobacco industry interference, which necessitates strict adherence to FCTC Article 5.3 to protect public health policies from commercial vested interests. Thailand’s ongoing four-decade confrontation with the tobacco industry and New Zealand’s recent reversal of its ambitious "endgame" legislative package illustrate that even rigorous, evidence-based policies remain politically fragile without durable cross-party consensus and strict firewalls. Furthermore, novel nicotine products, such as e-cigarettes and heated tobacco, are increasingly utilized by the industry to access policymaking processes under the guise of harm reduction. To ensure durable population-level reductions in tobacco use, the following structural features are recommended: (1) Implement the full MPOWER package simultaneously rather than relying on isolated measures. (2) Establish earmarked, transparent financing insulated from annual budget politics. (3) Enact and continuously monitor strict Article 5.3 firewalls across all government branches, including regulations for novel nicotine products. (4) Invest in sustained tobacco industry denormalization (TID) to educate the public and policymakers about industry tactics. (5) Foster regional technical and diplomatic solidarity to support smaller nations in translating FCTC obligations into enforceable laws.
  • Nurhayati Mohd Marzuki Speaker Malaysia
    “Systems Thinking” in Cessation: Situating Cessation as an Integral Service Within Primary Care and Pulmonary Medicine Nurhayati Mohd Marzuki, Institut Perubatan Respiratori, Kuala Lumpur, Malaysia Background: Smoking cessation is among the most effective treatments in respiratory medicine, yet it is rarely delivered as a routine service. In Malaysia, 85% of smokers intend to quit, and primary care doctors ask and advise almost every smoker, but only half arrange follow-up. We describe a systems approach to cessation at a tertiary respiratory centre, Institut Perubatan Respiratori (IPR), Kuala Lumpur. Methods: We framed cessation as a system with four parts: identification, treatment at first contact, continuation after discharge, and feedback of outcomes. Smoking status was built into the admission nursing assessment. Staff of all ranks were trained as Certified Smoking Cessation Service Providers (CSCSP). Nurses and pharmacists identify, advise and counsel; doctors prescribe nicotine replacement therapy (NRT) on the ward. After discharge, patients continue at IPR's daily Quit Smoking Clinic (Klinik Berhenti Merokok, KBM) or at a cessation centre nearer home. We reviewed service data from 2020 to 2025. Results: Eighty-one staff across seven cadres are CSCSP-certified. Annual KBM patients rose from 119 in 2020 to 233 in 2025. The 6-month carbon monoxide-verified quit rate among clinic attenders rose from 11.9% in the first half of 2023 to 29.2% in the second half of 2025. In 2025, 211 inpatients started NRT on the ward and 102 were referred to KBM. Outcomes for the remaining patients, who continued elsewhere or defaulted, are not captured. Conclusion: A ward-initiated, whole-team model was associated with greater cessation activity and higher quit rates at a Malaysian respiratory centre. The missing component is feedback on patients referred out. Cochrane evidence shows that support continuing beyond one month after discharge increases quitting (RR 1.36). We therefore propose a shared referral and outcome register, intention-to-treat reporting, and a named primary care partner to close the loop.
  • Ser Hon Puah Speaker Singapore
  • Henry Marshall Speaker Australia
    Nurhayati Mohd Marzuki Speaker Malaysia
Function Room 7, Ground Mezzanine Floor

20 November 2026, Friday

Time Session
13:00
14:00

21 November 2026, Saturday

Time Session
11:00
12:30
Henry Marshall Chairperson Australia
Ser Hon Puah Chairperson Singapore
  • Coral Gartner Speaker Australia
    The dominant nicotine product commercially marketed remains the combustible cigarette. However, the range of nicotine products being manufactured and marketed has continued to expand over the past two decades. These include nicotine vaping products, heated tobacco products, and oral nicotine products, such as nicotine pouches. The growth in use of high strength nicotine products in non-traditional forms among adolescents and young adults and the concurrent use of multiple nicotine products, including cigarettes and other combustible tobacco products, are key concerns. Globally, governments have taken different approaches to regulating the full range of nicotine products, applying various strategies to reduce potential health risks associated with their uptake. This presentation will give an overview of trends in use, recent market developments, and discuss some examples of differences between countries that have taken different approaches to nicotine product regulation.
  • Amer Siddiq Amer Nordin Speaker Malaysia
    Tobacco dependence remains a major preventable cause of respiratory disease, with its burden concentrated in low- and middle-income countries (LMICs), where access to cessation treatment is limited. This presentation examines tobacco control and smoking cessation across ASEAN, integrating regional epidemiology, Malaysian research and the recommendations published by Bullen and colleagues in the Asia-Pacific Journal of Public Health in 2026. Malaysian International Tobacco Control studies demonstrate substantial interest in quitting alongside widespread experimentation with emerging tobacco products. Findings on heated tobacco use and perceived harmfulness underscore the importance of assessing all nicotine products and distinguishing reduced toxicant exposure from established reductions in respiratory risk. Evidence from LMICs supports integrating behavioural interventions into existing tuberculosis, HIV, noncommunicable disease and primary care services. Effective pharmacotherapies are available, but affordability, licensing, procurement and supply constrain their use. Respiratory services can address these gaps through routine brief advice, appropriate medication, coordinated referral and continued follow-up. Workforce development, including Malaysia’s SCOPE training programme, can improve professional knowledge and confidence, although effects on patient outcomes require further evaluation. Group-based cessation offers an additional delivery option, supported by international evidence and Malaysian feasibility research. Digital support and shared clinical records may extend continuity beyond individual consultations. Sustainable implementation requires accessible medicines, locally adapted training and evaluation of treatment uptake and abstinence. Tobacco dependence treatment should become a routine component of respiratory care, supported by equitable financing and regional collaboration
  • Suthat Rungruanghiranya Speaker Thailand
    "The tobacco industry acts as the primary ""commercial vector"" driving global non-communicable diseases (NCDs), responsible for approximately 8 million deaths annually and an economic burden of $1.5 trillion. Drawing from clinical and public health evidence presented at APSR 2026, this session examines the multi-faceted tactics employed by tobacco corporations to undermine tobacco control policies, manipulate scientific discourse, and delay life-saving regulations across the Asia-Pacific region. Through a strategic ""policy dystopia"" framework, the industry utilizes discursive narratives—such as warning of economic loss, illicit trade, and legal violations—alongside instrumental strategies, including lobbying non-health government ministries and establishing front groups like ENDS Cigarette Smoke Thailand (ECST). Corporate tactics routinely stall legislation, resulting in years of unenforced acts and policy rollbacks in countries such as Papua New Guinea, Myanmar, Lao PDR, Malaysia, Indonesia, and Thailand. Furthermore, the industry exploits public health crises, such as COVID-19, through corporate social responsibility (CSR) initiatives and tobacco-leaf vaccine research to gain unmonitored access to government officials. To distort scientific reality, the industry promotes ""switch vs. quit"" narratives and funds biased research, with 65% of heated tobacco comparisons being industry-affiliated and 100% of biomarker trials carrying a high risk of bias. Simultaneously, corporations target healthcare professionals through sponsored continuing medical education (CME) and infiltrate the pharmaceutical sector—such as acquiring respiratory inhaler manufacturers—creating a profound ethical conflict by profiting concurrently from tobacco-caused diseases and their treatments. To counter these commercial determinants of health, public health strategies must strictly enforce Article 5.3 of the WHO Framework Convention on Tobacco Control (FCTC) across the whole of government. Comprehensive defense requires enforcing zero-conflict policies, complete transparency, binding codes of conduct, and restricted official interaction. Ultimately, health authorities should adopt the **TARGET** roadmap—focusing on Tobacco endgame, Accelerating MPOWER, Reducing nicotine levels, Generation nicotine-free policies, Eliminating interference, and Tobacco industry denormalization—to isolate the vector and safeguard public health."
  • Q&A
Ballroom 4, Lower Ground Floor